Final analysis of the Keynote-826 phase III trial, has shown that adding pembrolizumab to chemotherapy has increased progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. Following randomization of 617 patients, those who received bevacizumab indicated "grade >3 treatment-related adverse events occurred in 74% of patients in the pembrolizumab arm and 66.8% in the placebo arm."
To learn more about the Keynote-826 trial, click here.
Source mentioned:
Lorusso D, Colombo N, Dubot C, et al. Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study. Annals of Oncology; Published online 9 October 2024. DOI: https://doi.org/10.1016/j.annonc.2024.10.002
No comments:
Post a Comment